{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 464211168
| IUPAC_name = potassium&nbsp;3-[(8''R'',9''S'',10''R'',13''S'',14''S'',17''R'')-<br />17-hydroxy-10,13-dimethyl-3-oxo-2,8,9,<br />11,12,14,15,16-octahydro-1''H''-cyclopenta[a]<br />phenanthren-17-yl]propanoate
| image = Potassium canrenoate.svg
| width = 250px

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|potassium-canrenoate}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration = [[Intravenous therapy|Intravenous]]

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism = [[Liver|Hepatic]]
| elimination_half-life =  
| excretion = [[Kidney|Renal]] and fecal

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 2181-04-6
| ATC_prefix = C03
| ATC_suffix = DA02
| PubChem = 23671691
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB09015 
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1371200
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 570975
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = M671F9NLEA
| synonyms = SC-14266

<!--Chemical data-->
| chemical_formula =  
| C=22 | H=29 | K=1 | O=4 
| molecular_weight = 396.5616 g/mol
| smiles = [K+].[O-]C(=O)CC[C@]3(O)CC[C@H]2[C@@H]4/C=C\C1=C\C(=O)CC[C@@]1([C@H]4CC[C@@]23C)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C22H30O4.K/c1-20-9-5-15(23)13-14(20)3-4-16-17(20)6-10-21(2)18(16)7-11-22(21,26)12-8-19(24)25;/h3-4,13,16-18,26H,5-12H2,1-2H3,(H,24,25);/q;+1/p-1/t16-,17+,18+,20+,21+,22-;/m1./s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = JTZQCHFUGHIPDF-RYVBEKKQSA-M
}}

'''Potassium canrenoate''' ([[International Nonproprietary Name|INN]], [[Japanese Accepted Name|JAN]]) or '''canrenoate potassium''' ([[United States Adopted Name|USAN]]) (brand names '''Venactone''', '''Soldactone'''), also known as '''aldadiene kalium''',<ref name="Selye2013">{{cite book|author=Hans Selye|title=Hormones and Resistance: Part 1 and|url=https://books.google.com/books?id=NdvnCAAAQBAJ&pg=PA186|date=17 April 2013|publisher=Springer Science & Business Media|isbn=978-3-642-65192-2|pages=186–}}</ref> the [[potassium]] [[salt (chemistry)|salt]] of [[canrenoic acid]], is an [[aldosterone antagonist]] of the [[spirolactone]] group.<ref name="HillMakin1991">{{cite book|author1=R.A. Hill|author2=H.L.J. Makin|author3=D.N. Kirk|author4=G.M. Murphy|title=Dictionary of Steroids|url=https://books.google.com/books?id=qw5X0NK1A90C&pg=PA656|date=23 May 1991|publisher=CRC Press|isbn=978-0-412-27060-4|pages=656–}}</ref> Like [[spironolactone]], it is a [[prodrug]], and is [[drug metabolism|metabolized]] to active [[canrenone]] in the body.<ref name="BurgerWolff1996">{{cite book|author1=Alfred Burger|author2=Manfred E. Wolff|title=Burger's Medicinal Chemistry and Drug Discovery: Therapeutic agents|url=https://books.google.com/books?id=iLvwAAAAMAAJ|year=1996|publisher=Wiley|isbn=978-0-471-57557-3}}</ref><ref name="WaldmannSoni2008">{{cite book|author1=Carl Waldmann|author2=Neil Soni|author3=Andrew Rhodes|title=Oxford Desk Reference: Critical Care|url=https://books.google.com/books?id=eLqMpXfAlEcC&pg=PA187|date=27 November 2008|publisher=OUP Oxford|isbn=978-0-19-922958-1|pages=187–}}</ref>

Potassium canrenoate is notable in that it is the only clinically used antimineralocorticoid which is available for [[parenteral]] [[route of administration|administration]] (specifically [[intravenous]])<ref name="WaldmannSoni2008" /><ref name="Bonjer2017">{{cite book|author=H. Jaap Bonjer|title=Surgical Principles of Minimally Invasive Procedures: Manual of the European Association of Endoscopic Surgery (EAES)|url=https://books.google.com/books?id=tAImDwAAQBAJ&pg=PA136|date=21 June 2017|publisher=Springer|isbn=978-3-319-43196-3|pages=136–}}</ref> as opposed to [[oral administration]].<ref name="pmid28634268">{{cite journal | vauthors = Kolkhof P, Bärfacker L | title = 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development | journal = J. Endocrinol. | volume = 234 | issue = 1 | pages = T125–T140 | year = 2017 | pmid = 28634268 | doi = 10.1530/JOE-16-0600 | url = }}</ref>

==See also==
* [[Canrenoic acid]]
* [[Canrenone]]

==References==
{{Reflist|2}}

{{Diuretics}}
{{Antimineralocorticoids}}
{{Antiandrogens}}
{{Mineralocorticoidics}}
{{Progestogenics}}
{{Androgenics}}

[[Category:11β-Hydroxylase inhibitors]]
[[Category:Aldosterone synthase inhibitors]]
[[Category:Antimineralocorticoids]]
[[Category:Antiandrogens]]
[[Category:CYP17A1 inhibitors]]
[[Category:Pregnanes]]
[[Category:Potassium compounds]]
[[Category:Prodrugs]]
[[Category:Progestogens]]
[[Category:Propionates]]

{{cardiovascular-drug-stub}}